Jade Biosciences/$JBIO
1D1W1MYTD1Y5YMAX
Capital at risk
About Jade Biosciences
Jade Biosciences Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its flagship candidate, JADE101, targets the cytokine APRIL and is in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. The company's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an antibody candidate in preclinical development.
- Ticker
- $JBIO
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 55
- Headquarters
- Waltham, United States
- Website
- jadebiosciences.com
Jade Biosciences Metrics
BasicAdvanced
$1.2B
-
-$2.34
-
-
Price and volume
Market cap
$1.2B
52-week high
$28.00
52-week low
$6.91
Average daily volume
835K
Financial strength
Current ratio
14.927
Quick ratio
14.609
Long term debt to equity
0.001
Total debt to equity
0.003
Interest coverage (TTM)
-45.76%
Profitability
EBITDA (TTM)
-164.702
Effective tax rate (TTM)
-0.06%
Management effectiveness
Valuation
Price to book
2.63
Price to tangible book (TTM)
2.63
Price to free cash flow (TTM)
-7.813
Free cash flow yield (TTM)
-12.80%
Free cash flow per share (TTM)
-2.327
Growth
Bulls say / Bears say
Interim Phase 1 data for JADE101 delivered ~70% sustained serum IgA reductions at 12 weeks post-dose, supporting a potential best-in-class profile and quarterly subcutaneous dosing in IgA nephropathy (Yahoo Finance).
As of June 30, 2026, Jade held $461.2 million in cash, cash equivalents, and investments, providing runway into the fourth quarter of 2028 and reducing near-term financing risk (Jade Biosciences Press Release).
Jade dosed the first participant in its first-in-human Phase 1 trial of JADE201, an afucosylated anti-BAFF-R monoclonal antibody, demonstrating progress in expanding its autoimmune pipeline beyond JADE101 (Yahoo Finance).
The $172.5 million public offering in August 2026 at $15.00 per share will substantially increase share count, leading to significant dilution for existing shareholders (Investing.com).
Net loss widened to $55.8 million in Q2 2026 versus $32.1 million a year ago, driven by rising R&D and G&A expenses, indicating accelerating cash burn ahead of product revenues (Jade Biosciences Press Release).
JADE101’s clinical efficacy in patients is unproven as the Phase 2 trial only initiated recently with interim data not expected until 2027, leaving a significant translational risk gap (Yahoo Finance).
Data summarised monthly by Lightyear AI. Last updated on 23 Aug 2026.
Upcoming events
No upcoming events
Funds containing Jade Biosciences
AllEURUSDGBP
Fund name | Fund size | $JBIO weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.02% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.01% |
iShares MSCI World Small Cap£WLDS | £6.7B | 0.01% |
SPDR MSCI All Country World IM€SPYI | €7.5B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.